Morgan Stanley (MS)

Longboard Pharmaceuticals Stock Forecast

Stock Price Forecast

The 12 analysts that cover Longboard Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $138.25, which forecasts a -1.89% decrease in the stock price over the next year. The lowest target is $122 and the highest is $160.

Price Target: $138.25 (-1.89%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$122	$138.25	$138	$160
Change	-13.43%	-1.89%	-2.07%	+13.54%

* Price targets were last updated on Jul 9, 2025.

Analyst Ratings

The average analyst rating for Longboard Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	3	2	2	2	2	2
Buy	3	3	3	3	4	3
Hold	10	10	10	10	9	8
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	16	15	15	15	15	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
David Konrad Keefe, Bruyette & Woods	Keefe, Bruyette & Woods	Hold → Buy Upgrades $127 → $160	Hold → Buy	Upgrades	$127 → $160	+13.54%	Jul 9, 2025
Mike Mayo Wells Fargo	Wells Fargo	Hold Maintains $120 → $145	Hold	Maintains	$120 → $145	+2.90%	Jul 8, 2025
Keith Horowitz Citigroup	Citigroup	Hold Maintains $125 → $130	Hold	Maintains	$125 → $130	-7.75%	Jun 18, 2025
Richard Ramsden Goldman Sachs	Goldman Sachs	Hold Maintains $121 → $136	Hold	Maintains	$121 → $136	-3.49%	Jun 10, 2025
Richard Ramsden Goldman Sachs	Goldman Sachs	Hold Maintains $122 → $121	Hold	Maintains	$122 → $121	-14.14%	Apr 25, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

69.25B

Increased by 12.60%

from 61.50B

Revenue Next Year

72.36B

Increased by 4.49%

from 69.25B

EPS This Year

8.87

Increased by 11.55%

from 7.95

EPS Next Year

9.65

Increased by 8.84%

from 8.87

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	48.00B	59.75B	53.39B	53.61B	61.50B	69.25B	72.36B	75.39B
Revenue Growth	16.00%	24.49%	-10.65%	0.42%	14.71%	12.60%	4.49%	4.19%
EPS	6.46	8.03	6.15	5.18	7.95	8.87	9.65	10.72
EPS Growth	24.47%	24.30%	-23.41%	-15.77%	53.47%	11.55%	8.84%	11.06%
Forward PE	-	-	-	-	-	15.89	14.60	13.15
No. Analysts	-	-	-	-	-	27	27	15

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	71.3B	75.9B	79.1B
Avg	69.2B	72.4B	75.4B
Low	65.1B	65.5B	67.9B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	15.9%	9.5%	9.3%
Avg	12.6%	4.5%	4.2%
Low	5.9%	-5.3%	-6.2%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	9.56	10.65	11.91
Avg	8.87	9.65	10.72
Low	7.97	8.65	9.59

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	20.2%	20.1%	23.4%
Avg	11.6%	8.8%	11.1%
Low	0.2%	-2.4%	-0.6%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.